Julia Lai-Kwon, Medical Oncologist and PhD candidate at the Peter MacCallum Cancer Centre, shared a post Christina Yap, Professor of Clinical Trials Biostatistics at The Institute of Cancer Research on LinkedIn, adding:
“Thank you to Christina Yap and Emily Alger for leading this work. It is great to see our early work in PROs in early phase dose finding oncology trials coming to fruition. Looking forward to disseminating this work locally!”
Quoting Christina Yap‘s post:
“Delighted to share our latest OPTIMISE‑AR publication in The Lancet Oncology!
Our newly published OPTIMISE‑AR paper introduces a practical toolkit to support the analysis and vizualisation of patient‑reported outcomes (PROs) in early‑phase dose‑finding oncology trials. This work addresses an important gap: while PROs are increasingly recognized as vital in early phase studies, there has been no guidance on which PRO objectives to assess or how best to analyze and present these data.
Building on OPTIMISE‑ROR, which sets out the key PRO objectives to consider in dose‑finding trials, OPTIMISE‑AR brings together a multidisciplinary international group of stakeholders to develop an analytical toolkit that directly addresses these objectives.
This work is designed to help trialists integrate patient perspectives earlier in clinical development, enhancing understanding of tolerability, informing dose optimization, and ultimately supporting more patient‑centred decision‑making.”
Title: A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR)
Authors: Emily Alger, Antoine Regnault, Amylou C. Dueck, Madeline Pe, Michael J. Grayling, Melanie J. Calvert, Aaron R. Hansen, Olga Kholmanskikh, Julia Lai-Kwon, J. Jack Lee, Anna Minchom, Yu Qiao, Khadija Rerhou Rantell, Jessica Roydhouse, Claire Snyder, Stefan N. Symeonides, Nolan A. Wages, Roger Wilson, Christina Yap
Read The Full Article
Other articles on OncoDaily.